Research groups
Colleges
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Recent publications
-
Dose-dependent and tissue-specific adverse effects of exogenous glucocorticoids: insights for optimizing clinical practice.
Journal article
Pofi R. et al, (2025), J Endocrinol Invest
-
The impact of estrogen deficiency on liver metabolism; implications for hormone replacement therapy
Journal article
Dong J. et al, (2025), Endocrine Reviews
-
Dissecting metabolic dysfunction- and alcohol-associated liver disease (MetALD) using proteomic and metabolomic profiles.
Journal article
Liu J. et al, (2025), J Hepatol
-
Severe Dietary Energy Restriction for Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomised Controlled Trial.
Journal article
Koutoukidis DA. et al, (2025), J Cachexia Sarcopenia Muscle, 16
-
Is It Possible to Screen for Primary Aldosteronism Effectively in Primary Care?
Journal article
Dissanayake HA. et al, (2025), Clin Endocrinol (Oxf)